Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Biomedical Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 2049-9434 Online ISSN: 2049-9442
Journal Cover
May-June 2013 Volume 1 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
May-June 2013 Volume 1 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Biochemical index and immunological function in the peripheral blood of patients with idiopathic pulmonary alveolar proteinosis

  • Authors:
    • Jiuwu Bai
    • Huiping Li
    • Jingyun Shi
    • Jinfu Xu
    • Xia Li
    • Weijun Cao
    • Haiqing Chu
    • Jinming Liu
    • Beilan Gao
  • View Affiliations / Copyright

    Affiliations: Department of Respiratory Medicine, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, P.R. China, Department of Radiology, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, P.R. China
  • Pages: 405-409
    |
    Published online on: February 20, 2013
       https://doi.org/10.3892/br.2013.66
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Idiopathic pulmonary alveolar proteinosis (PAP) has recently been recognized as a disease of impaired alveolar macrophage function caused by the neutralizing granulocyte-macrophage colony stimulating factor (GM-CSF) autoantibody. However, the change of immunological function and biochemical index in the peripheral blood of patients with idiopathic PAP remains unclear. The clinical data of 29 patients with idiopathic PAP and 30 normal subjects were retrospectively analyzed. Biochemical indices, immunoglobulin and complement of all participants, and immunocytes in 19 patients and 30 normal subjects were evaluated. The peripheral blood of the patients showed a decrease in CD4+/CD8+ (P<0.05) and the percentage of the CD4+ T lymphocyte and helper T lymphocyte (both P<0.01), whereas an increase was observed in the percentage of the suppressor T lymphocyte (P<0.01) compared to the normal subjects. No significant differences were found in the concentration of IgG, IgA, IgM, C3 and C4 between the two groups. An increase was observed in LDH (P<0.01) and cytokeratin fragment antigen (CYFR) 211 (P<0.01) in the peripheral blood of the patients compared to that of normal subjects. The serum level of LDH was negatively correlated with FVC% Pred (P<0.05), DLCO% Pred (P<0.05), PaO2 (P<0.05) and positively associated with the dyspnea score (P<0.05) of 29 patients, and positively correlated with the score of high-resolution computed tomography (HRCT) of the chest of 21 patients (P<0.05). The serum level of CYFR211 was negatively correlated with DLCO% Pred (P<0.05) and positively associated with the dyspnea score (P<0.05). Findings of the present study suggest that hypofunction of cellular immunity may exist in the patients with idiopathic PAP. LDH and CYFRA211 may be considered as important indices to monitor the severity of idiopathic PAP.

Introduction

Pulmonary alveolar proteinosis (PAP), a rare lung disease of unknown origin, is characterized by the accumulation of the alveoli with phospholipid, protein and other floccular material that stain with periodic acid-Schiff. The existence of PAP was only recognized in 1958 through the seminal report of Rosen et al(1). Carey and Trapnell (2) classified PAP into three groups, i.e., congenital, autoimmune and secondary PAP. Congenital PAP is a heterogeneous collection of disorders caused by homozygous mutation of the genes encoding surfactant protein (SP)-B, SP-C and the ABCA3 transporter or by the absence of the granulocyte/macrophage colony stimulating factor (GM-CSF) receptor. Congenital PAP usually occurs in children. Secondary PAP has been reported in association with various diverse clinical disorders such as hematological disorders, immunological diseases, lysinuric protein intolerance and infections, and various toxic inhalation syndromes, including inhalation of inorganic and organic dusts, and fumes. Autoimmune PAP is also regarded as a type of idiopathic PAP.

In this study, idiopathic PAP was employed instead of autoimmune PAP. Ninety per cent of patients have idiopathic PAP, with a prevalence of 6–7 individuals per million in the general population. Additionally, idiopathic PAP occurs in all ethnic groups, in the third to fourth decades of life and is approximately twice as common in males. The presence of idiopathic PAP may be associated with high levels of neutralizing GM-CSF autoantibody (2,3). High levels of GM-CSF autoantibody are associated with idiopathic PAP, and these autoantibodies are assumed to be critical in the pathogenesis of idiopathic PAP, but are not present in secondary or congenital PAP, other lung diseases or in healthy donors (4). The binding affinity of autoantibodies for GM-CSF is higher than that for the GM-CSF receptor in its low- or high-affinity binding state, and these autoantibodies eliminate GM-CSF bioactivity in vivo(5). Subsequently, idiopathic PAP is a type of autoimmune disorder. However, systemic studies regarding the immunological function and biochemical index of idiopathic PAP have yet to be conducted. In the present study, some pathogenesis of idiopathic PAP was explored, through the detection of immunocytes, immunoglobulin (Ig), complement (C), cytokeratin fragment antigen 211 (CYFR211), lactate dehydrogenase (LDH) and creatine kinase (CK) in the peripheral blood of patients with idiopathic PAP.

Materials and methods

Subjects

During the 11-year period between 2000 and 2010, a series of 42 Chinese patients who were diagnosed with PAP in the Shanghai Pulmonary Hospital Affiliated to Tongji University (Shanghai, China) were retrospectively analyzed. In this study, the eligibility criteria used were as proposed by Kavuru et al(6) and included: i) histopathological findings of specimens obtained by open lung biopsy or transbronchial lung biopsy; ii) a milk-like appearance with typical cytologic findings of bronchoalveolar lavage (BAL); iii) high-resolution computed tomography (HRCT) scan which showed ground glass opacity and/or a pattern of crazy paving; iv) restrictive ventilation and diffusion dysfunction, hypoxemia; with v) dyspnea and cough being the most common symptoms, although certain patients were asymptomatic at diagnosis. Exclusion criteria for this study were: i) PAP resulting from another condition (e.g., myeloproliferative disorder or leukemia, occupational exposure to dust, human immunodeficiency virus disease or respiratory infections) and ii) age <18 years. The diagnosis of PAP was based on BAL and the histopathological findings of specimens obtained by open lung biopsy in eight patients, by transbronchial lung biopsy in three patients and by only BAL in 31 patients (6,7). Thirteen patients, including 5 steelworkers, 2 mineworkers, 2 steelworkers and 4 persons with long-term contact history to oil fume were excluded from the study. An additional 29 patients had no induction agent, but were diagnosed with idiopathic PAP and included in this study.

Control group

Between 2000 and 2010, 30 healthy adults who had no medical histories were randomly selected following examination in the clinic, and were classified as normal subjects (Table I). All study participants provided informed consent.

Table I

Characteristics of the patients and normal subjects.

Table I

Characteristics of the patients and normal subjects.

CharacteristicsPatients (n=29)Normal subjects (n=30)P-value
Gender (male/female)19/1020/10
Mean age (years)47.8±10.645.8±14.1
Smoking status
  Current smoker1113
  Ex-smoker34
  Never-smoker1513
Symptom
  Dyspnea14
  Dry cough11
  Expectoration10
  Thoracalgia5
Dyspnea score1.17±1.04
Score of chest HRCT19.10±9.01
FVC% Pred72.26±19.1295.97±8.370.000
FEV1% Pred71.79±18.3695.58±7.830.000
FEV1/FVC83.09±5.7083.47±5.610.655
DLCO%61.56±24.10102.49±11.250.000
PaO2 (mmHg)71.32±14.7694.13±2.990.000

[i] Values are shown as the mean ± SD. HRCT, high-resolution computed tomography; FVC% Pred, forced vital capacity/predicted value; FEV1% Pred, forced expiratory volume in one second/predicted value; DLCO% Pred, diffusing capacity of the lung for carbon monoxide; PaO2, arterial partial pressure of oxygen.

Dyspnea score

Dyspnea was one of the most common symptoms. The dyspnea score was measured with the Modified British Medical Research Council (mMRC). The grade of dyspnea was from 0 to 4 (I only get breathless with strenuous exercise, 0; I get short of breath when hurrying on the level or walking up a slight hill, 1; I walk slower than people of the same age on the level due to breathlessness or I have to stop for breath when walking on my own pace on the level, 2; I stop for breath after walking ∼100 m or after a few minutes on the level, 3; I am too breathless to leave the house or I am breathless when dressing or undressing, 4).

Score of chest HRCT

The high-resolution computed tomography (HRCT) of chest was analyzed for 21 patients. The chest HRCT of an additional 8 patients had been examined in other hospitals, but records were inadequate. HRCT scans of the chest were graded according to the visual scoring methods proposed by Lee et al(8). The chest radiographs were read and interpreted independently by a radiologist and a respiratory medicine physician. The mean values obtained from the two readers were used for analysis. The scores were decided on four representative layers including aortic arch, tracheal carina, left/right inferior lung vein converging and above of diaphragm layer score (Fig. 1). The ‘ground glass opacity’ referred to the presence of increased lung opacity associated with partial obscuring of normal vascular structures. The extent of lung opacity was estimated by means of a five-point scale as: no opacity, 0; opacity involving <25% of a layer of hemithorax, 1; ≥25 – <50%, 2; ≥50 – <75%, 3; ≥75%, 4. The score of chest HRCT was calculated by adding up the extent scores on the four representative layers of each hemithorax.

Figure 1

Score on four representative layers. (A) Aortic arch layer score (right, 1; left, 0); (B) tracheal carina layer score (right, 2; left, 2); (C) left/right inferior lung vein converging layer score (right, 4; left, 3); (D) above of the diaphragm layer score (right, 4; left, 3).

Pulmonary function

The patients and normal subjects underwent pulmonary function testing using a MasterScreen spirometer (Jaeger GmbH, Würzburg, Germany). Pulmonary function testing, including forced vital capacity/predicted value (FVC% Pred), forced expiratory volume in one second/predicted value (FEV1% Pred), FEV1/FVC and diffusing capacity of the lung for carbon monoxide/predicted value (DLCO% Pred), was performed. Blood samples were analyzed for arterial partial pressure of oxygen (PaO2) values in room air using a Blood-gas analyzer (Radiometer, Copenhagen, Denmark).

Immunological function and biochemistry

Immunocytes in the peripheral blood of 19 patients and normal subjects were detected using a flow cytometer (Beckman Coulter, Inc., Miami, FL, USA). IgG, IgA, IgM, C3, C4, LDH and CK in peripheral blood using a biochemical analyzer (Olympus Optical Co, Ltd., Japan), and CYFR211 in peripheral blood using a full automatic dual-head radioimmunoassay Gamma Counter (Shanghai Hesuo Rihuan Photoelectric Instrument Co., Ltd., China) were detected in all study participants.

Statistical analysis

Differences between the parameters of patients with idiopathic PAP and normal subjects were tested using a paired t-test. P<0.05 was considered statistically significant. All tests were two-sided. Results were reported as the mean ± SD. The correlation between variables was determined by Pearson’s correlation analysis. Statistical analysis was performed using SPSS version 15.

Results

Patient characteristics

The characteristics of the idiopathic PAP group were compared with those of the normal subjects group (Table I). The mean dyspnea score was shown as 1.17±1.04. There were various symptoms, including dyspnea (n=14), dry cough (n=11), expectoration (n=10) and thoracalgia (n=5) in 24 patients, but no symptoms occurred in other patients. The results of pulmonary function and PaO2 are listed in Table I. FVC% Pred, FEV1% Pred, DLCO% Pred and PaO2 were higher in the idiopathic PAP patients than those of normal subjects (all P<0.01). No differences were found in FEV1/FVC between the two groups (P>0.05). The mean score of chest HRCT of patients was 19.10±9.01. Significant correlations between the score of chest HRCT and the dyspnea score (r=−0.857; P=0.000), FVC% Pred (r=−0.657; P=0.001), FEV1% Pred (r=−0.565; P=0.004), DLCO% Pred (r=−0.733; P=0.000) and PaO2 (r=−0.685; P=0.000) were observed in 21 patients. However, no apparent correlations were observed between the score of chest HRCT and FEV1/FVC (r=0.349; P=0.143).

Immunological and biochemical indices of the patients and normal subjects, and Pearson’s correlation coefficient

The results of immunocytes in peripheral blood are listed in Table II. The peripheral blood of 19 patients demonstrated a decrease in CD4+/CD8+ (P<0.05), the percentage of CD4+ T lymphocyte (P<0.01) and helper T lymphocyte (P<0.01), and an increase in the percentage of suppressor T lymphocyte (P<0.01) compared to that of normal subjects. No correlations were found in the percentage of CD3+ T lymphocyte, natural killer and CD8+ T lymphocyte between the two groups (all P>0.05). No correlations were observed between any of factor including CD4+ T lymphocyte, CD4+/CD8+, helper T lymphocyte and suppressor T lymphocyte, and the dyspnea score, score of chest HRCT, FVC% Pred, FEV1% Pred, DLCO% Pred and PaO2, respectively (all P>0.05).

Table II

Immunological and biochemical index of the patients and normal subjects.

Table II

Immunological and biochemical index of the patients and normal subjects.

Idiopathic PAP patients
Normal subjects
Immunological and biochemical indexnMean ± SDnMean ± SDP-value
Immunocytes
  CD3+ (%)1970.5±6.03068.3±8.90.338
  NK (%)1916.2±17.6308.4±5.50.074
  CD4± (%)1934.6±10.63044.0±6.80.002
  CD8± (%)1928.1±10.03024.9±7.50.210
  CD4±/CD8±191.5±0.8302.0±0.80.033
  Th (%)190.5±0.16300.6±0.090.001
  Ts (%)190.4±0.1300.3±0.080.009
Immunoglobulin
  IgG (g/l)2910.7±3.83010.9±2.10.781
  IgA (g/l)292.7±1.8302.4±1.80.571
  IgM (g/l)291.4±0.8301.1±0.60.104
Complement
  C3 (g/l)291.5±1.7301.2±0.30.330
  C4 (g/l)290.4±0.1300.4±0.20.491
Biochemical index
  CYFRA211 (ng/ml)297.0±4.5301.0±0.60.000
  LDH (IU/l)29239.9±75.130155.3±31.10.000
  CK (IU/l)2984.3±69.03066.4±22.40.193

[i] CD3+, CD3+ T lymphocyte; NK, natural killer; CD4+, CD4+ T lymphocyte; CD8+, CD8+ T lymphocyte; Th, helper T lymphocyte; Ts, suppressor T lymphocyte; IgG, immunoglobulin G; IgA, immunoglobulin A; IgM, immunoglobulin M; C3, complement 3; C4, complement 4; CYFR211, cytokeratin fragment antigen 211; LDH, lactate dehydrogenase; CK, creatine kinase.

Pearson’s correlation coefficients (r) between the two variables are listed in Table III. The results of immunoglobulin and complement in peripheral blood are listed in Table II. No differences were observed in the concentration of IgG, IgA, IgM, C3 and C4 between the two groups (all P>0.05). The serum level of LDH, CYFRA211 and CK are listed in Table II. An increase was found in the LDH (t=7.191; P<0.01) and CYFR211 (t=5.622; P<0.01) in the peripheral blood of the patients compared to that of normal subjects, but there were no differences in the concentration of CK between the two groups (P>0.05). The serum level of LDH was negatively correlated with FVC% Pred (r=−0.400; P=0.032), DLCO% Pred (r=−0.604; P=0.001), PaO2 (r=−0.395; P=0.034), positively associated with the dyspnea score (r=0.645; P=0.000) in 29 patients with idiopathic PAP, and positively correlated with the score of chest HRCT in 21 patients (r=0.494; P=0.023). There was no correlation between LDH and any of the FEV1% Pred (r=−0.345; P=0.067) or FEV1/FVC (r=−0.140; P=0.468), respectively. The serum level of CYFR211 was negatively correlated with DLCO% Pred (r=−0.401; P=0.031), and positively associated with the dyspnea score (r=0.403; P=0.030). However, no correlation was found between FVC% Pred (r=−0.256; P=0.180), FEV1% Pred (r=−0.224; P=0.243), FEV1/FVC (r=0.309; P=0.103) and PaO2 (r=−0.171; P=0.374) in any of the patients with idiopathic PAP and the score of chest HRCT (r=0.341; P=0.131) of 21 patients.

Table III

Pearson’s correlation coefficient (r) between the two variables.

Table III

Pearson’s correlation coefficient (r) between the two variables.

CharacteristicCD4+ (%) CD4+/CD8+Th (%)Ts (%)
Dyspnea score0.1800.2940.2320.402
FVC% Pred0.1670.0990.3170.165
FEV1% Pred0.1130.0070.2300.233
DLCO% Pred0.2640.2700.2860.434
PaO2 (mmHg)0.0800.0250.0620.098
Score of chest
HRCT0.0020.0500.1670.043

[i] FVC% Pred, forced vital capacity/predicted value; FEV1% Pred, forced expiratory volume in one second/predicted value; DLCO% Pred, diffusing capacity of the lung for carbon monoxide/predicted value; PaO2, arterial partial pressure of oxygen; HRCT, high-resolution computed tomography.

Discussion

By summarizing previous studies for over 50 years Carey and Trapnell (2) showed that idiopathic PAP was regarded as being strongly associated with high levels of the neutralizing GM-CSF autoantibody (9,10). Additionally, secondary PAP was associated with various diverse clinical disorders and various toxic inhalation syndromes. Findings of Costabel and Nakata (11) indicated that inhalation of dusts may be the initiating cause which resulted in the elevation of the neutralizing GM-CSF autoantibody. Thus, the cause of idiopathic PAP and the reason for the elevated levels of the GM-CSF autoantibody remain to be investigated.

Dyspnea was observed as the most dominant symptom of patients with idiopathic PAP in Korean and Japanese populations (9,12) and 17 patients in this study (58.6%). Results of pulmonary function in this study were similar to those of previous studies (12), i.e., a restrictive defect, with a reduction in the diffusing capacity. Arterial blood gas analysis was found to exhibit hypoxemia in previous studies as well as this one (10,12). Chest HRCT objectively showed the degree, extent and severity of lung opacity and was a key external index used to evaluate the severity of PAP. Correlations between pulmonary function testing and HRCT parameters were found by Chen et al(13), with significance in average lung density and FVC, total lung mass and FEV1, the ratio of air-filling lung volume to total lung volume and peak expiratory flow, DLCO and the ratio of DLCO to alveolar volume. Correlation analyses that were performed between quantitative CT parameters and DLCO and PaO2 by Guan et al(14) indicated that DLCO correlated well with the total lung weight, airspace volume, mean lung density, and mean lung inflation, and that PaO2 also correlated well with the total lung weight, mean lung density, mean lung inflation and airspace volume/total lung volume ratio. In this study, significant correlations were noted between the score of chest HRCT, dyspnea score, and FVC% Pred, FEV1% Pred, DLCO% and PaO2, respectively. Thus, the severity of idiopathic PAP was reflected by the dyspnea score, score of chest HRCT, pulmonary function and PaO2 to a great extent.

CD4+ T lymphocyte is able to promote the multiplication and differentiation of B lymphocytes, T lymphocytes and other immunocytes, and coordinate the interaction between variants of immunocytes. The helper T lymphocyte is the regulatory T cell. The suppressor T lymphocyte is one of the CD8+ T lymphocytes which released inhibitory factors and acted on the antigen-specific helper T and/or B lymphocyte and led to immunological function suppression. The peri pheral blood of the patients showed a decrease in CD4+/CD8+, the percentage of CD4+ T lymphocyte and helper T lymphocyte, and an increase in the percentage of suppressor T lymphocyte. These results indicated that cellular immunity was inhibited. The correlation analysis between the significant immunocytes and dyspnea score, score of chest HRCT, lung function index and PaO2, indicated that these immunocytes were not associated with the severity of PAP. However, a predominance of CD4+ cells in some idiopathic PAP cases was reported previously (15). Thus, more studies should be conducted to determine the role of these cells in idiopathic PAP. Results obtained from the analysis of the immunoglobulin and complement indicated that humoral immunity had no correlation with PAP.

The serum level of LDH was increased in idiopathic PAP patients in previous studies (16,17). A significant correlation between LDH and alveolar artery oxygen gradient was detected by Xu et al(16). In this study, it was also found that LDH was elevated and was correlated with FVC% Pred, DLCO% Pred, PaO2, dyspnea score and the score of chest HRCT, suggesting a correlation with the severity of idiopathic PAP. A case of PAP was previously reported in which the value of cytokeratin 19 fragment in the serum was initially elevated and decreased to the normal range after the lung lavage (18). CYFRA211 was the soluble fragment of cytokeratin 19. In this study, the result showed that CYFRA211 increased in PAP, and had a significant cotrelation with DLCO% Pred and the dyspnea score. Those studies indicated that CYFRA211 may regarded as one of the indices to monitor the severity of idiopathic PAP.

In summary, the results of immunity (including cellular and humoral immunity) and the chemistry index in peripheral blood of patients with idiopathic PAP showed that hypo-function of cellular immunity existed. By contrast, humoral immunity was not involved with idiopathic PAP, LDH and CYFRA211, which may be regarded as important indices to monitor the severity of idiopathic PAP.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation (30971323) and partly by the Project of Academic Leaders in Excellent Disciplines of Shanghai in China (08XD1403400).

References

1 

Rosen SH, Castleman B and Liebow AA: Pulmonary alveolar proteinosis. N Engl J Med. 258:1123–1142. 1958. View Article : Google Scholar : PubMed/NCBI

2 

Carey B and Trapnell BC: The molecular basis of pulmonary alveolar proteinosis. Clin Immunol. 135:223–235. 2010. View Article : Google Scholar : PubMed/NCBI

3 

Sakagami T, Beck D, Uchida K, et al: Patient-derived granulocyte/ macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med. 182:49–61. 2010. View Article : Google Scholar

4 

Kitamura T, Tanaka N, Watanabe J, et al: Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med. 190:875–880. 1999. View Article : Google Scholar

5 

Uchida K, Nakata K, Trapnell BC, et al: High-affinity auto-antibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood. 103:1089–1098. 2004. View Article : Google Scholar

6 

Kavuru MS, Sullivan EJ, Piccin R, Thomassen MJ and Stoller JK: Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 161:1143–1148. 2000. View Article : Google Scholar

7 

Borie R, Danel C, Debray MP, et al: Pulmonary alveolar proteinosis. Eur Respir Rev. 20:98–107. 2011. View Article : Google Scholar

8 

Lee KN, Levin DL, Webb WR, Chen D, Storto ML and Golden JA: Pulmonary alveolar proteinosis: high-resolution CT, chest radiographic, and functional correlations. Chest. 111:989–995. 1997. View Article : Google Scholar : PubMed/NCBI

9 

Inoue Y, Trapnell BC, Tazawa R, et al: Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 177:752–762. 2008. View Article : Google Scholar : PubMed/NCBI

10 

Lin FC, Chang GD, Chern MS, Chen YC and Chang SC: Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis. Thorax. 61:528–534. 2006. View Article : Google Scholar : PubMed/NCBI

11 

Costabel U and Nakata K: Pulmonary alveolar proteinosis associated with dust inhalation: not secondary but autoimmune? Am J Respir Crit Care Med. 181:427–428. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Byun MK, Kim DS, Kim YW, et al: Clinical features and outcomes of idiopathic pulmonary alveolar proteinosis in Korean population. J Korean Med Sci. 25:393–398. 2010. View Article : Google Scholar : PubMed/NCBI

13 

Chen QL, Shen J, Gao Y, Guan YB, An JY and Zheng JP: Evaluation of correlation between pulmonary function testing and high resolution computed tomography in pulmonary alveolar proteinosis. Zhonghua Jie He He Hu Xi Za Zhi. 31:505–508. 2008.(In Chinese).

14 

Guan Y, Zeng Q, Yang H, et al: Pulmonary alveolar proteinosis: Quantitative CT and pulmonary functional correlations. Eur J Radiol. May 26–2011.(Epub ahead of print).

15 

Schoch OD, Schanz U, Koller M, et al: BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF. Thorax. 57:277–280. 2002. View Article : Google Scholar : PubMed/NCBI

16 

Xu KF, Chen Y, Guo ZJ and Zhu YJ: Autoantibody against granulocyte-macrophage colony-stimulating factor and other serum markers in pulmonary alveolar proteinosis. Zhonghua Jie He He Hu Xi Za Zhi. 27:824–828. 2004.(In Chinese).

17 

Inoue Y, Nakata K, Arai T, et al: Epidemiological and clinical features of idiopathic pulmonary alveolar proteinosis in Japan. Respirology. 11:S55–S60. 2006. View Article : Google Scholar : PubMed/NCBI

18 

Minakata Y, Kida Y, Nakanishi H, Nishimoto T and Yukawa S: Change in cytokeratin 19 fragment level according to the severity of pulmonary alveolar proteinosis. Intern Med. 40:1024–1027. 2001. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Bai J, Li H, Shi J, Xu J, Li X, Cao W, Chu H, Liu J and Gao B: Biochemical index and immunological function in the peripheral blood of patients with idiopathic pulmonary alveolar proteinosis. Biomed Rep 1: 405-409, 2013.
APA
Bai, J., Li, H., Shi, J., Xu, J., Li, X., Cao, W. ... Gao, B. (2013). Biochemical index and immunological function in the peripheral blood of patients with idiopathic pulmonary alveolar proteinosis. Biomedical Reports, 1, 405-409. https://doi.org/10.3892/br.2013.66
MLA
Bai, J., Li, H., Shi, J., Xu, J., Li, X., Cao, W., Chu, H., Liu, J., Gao, B."Biochemical index and immunological function in the peripheral blood of patients with idiopathic pulmonary alveolar proteinosis". Biomedical Reports 1.3 (2013): 405-409.
Chicago
Bai, J., Li, H., Shi, J., Xu, J., Li, X., Cao, W., Chu, H., Liu, J., Gao, B."Biochemical index and immunological function in the peripheral blood of patients with idiopathic pulmonary alveolar proteinosis". Biomedical Reports 1, no. 3 (2013): 405-409. https://doi.org/10.3892/br.2013.66
Copy and paste a formatted citation
x
Spandidos Publications style
Bai J, Li H, Shi J, Xu J, Li X, Cao W, Chu H, Liu J and Gao B: Biochemical index and immunological function in the peripheral blood of patients with idiopathic pulmonary alveolar proteinosis. Biomed Rep 1: 405-409, 2013.
APA
Bai, J., Li, H., Shi, J., Xu, J., Li, X., Cao, W. ... Gao, B. (2013). Biochemical index and immunological function in the peripheral blood of patients with idiopathic pulmonary alveolar proteinosis. Biomedical Reports, 1, 405-409. https://doi.org/10.3892/br.2013.66
MLA
Bai, J., Li, H., Shi, J., Xu, J., Li, X., Cao, W., Chu, H., Liu, J., Gao, B."Biochemical index and immunological function in the peripheral blood of patients with idiopathic pulmonary alveolar proteinosis". Biomedical Reports 1.3 (2013): 405-409.
Chicago
Bai, J., Li, H., Shi, J., Xu, J., Li, X., Cao, W., Chu, H., Liu, J., Gao, B."Biochemical index and immunological function in the peripheral blood of patients with idiopathic pulmonary alveolar proteinosis". Biomedical Reports 1, no. 3 (2013): 405-409. https://doi.org/10.3892/br.2013.66
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team